306 related articles for article (PubMed ID: 35386658)
1. Immunoglobulin E-Dependent Activation of Immune Cells in Rhinovirus-Induced Asthma Exacerbation.
Kawakami T; Kasakura K; Kawakami Y; Ando T
Front Allergy; 2022; 3():835748. PubMed ID: 35386658
[TBL] [Abstract][Full Text] [Related]
2. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma.
Esquivel A; Busse WW; Calatroni A; Togias AG; Grindle KG; Bochkov YA; Gruchalla RS; Kattan M; Kercsmar CM; Khurana Hershey G; Kim H; Lebeau P; Liu AH; Szefler SJ; Teach SJ; West JB; Wildfire J; Pongracic JA; Gern JE
Am J Respir Crit Care Med; 2017 Oct; 196(8):985-992. PubMed ID: 28608756
[TBL] [Abstract][Full Text] [Related]
3. Histamine-releasing factor in severe asthma and rhinovirus-associated asthma exacerbation.
Kawakami Y; Takazawa I; Fajt ML; Kasakura K; Lin J; Ferrer J; Kantor DB; Phipatanakul W; Heymann PW; Benedict CA; Kawakami Y; Kawakami T
J Allergy Clin Immunol; 2023 Sep; 152(3):633-640.e4. PubMed ID: 37301412
[TBL] [Abstract][Full Text] [Related]
4. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
[TBL] [Abstract][Full Text] [Related]
5. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
6. Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
D'Amato G; Bucchioni E; Oldani V; Canonica W
Treat Respir Med; 2006; 5(6):393-8. PubMed ID: 17154668
[TBL] [Abstract][Full Text] [Related]
7. Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
D'Amato G; Liccardi G; Noschese P; Salzillo A; D'Amato M; Cazzola M
Curr Drug Targets Inflamm Allergy; 2004 Sep; 3(3):227-9. PubMed ID: 15379589
[TBL] [Abstract][Full Text] [Related]
8. Innate Immune Responses by Respiratory Viruses, Including Rhinovirus, During Asthma Exacerbation.
Nakagome K; Nagata M
Front Immunol; 2022; 13():865973. PubMed ID: 35795686
[TBL] [Abstract][Full Text] [Related]
9. A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthma.
D'Amato G; Salzillo A; Piccolo A; D'Amato M; Liccardi G
Ther Clin Risk Manag; 2007 Aug; 3(4):613-9. PubMed ID: 18472983
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma.
García-Mochón L; Gil-Sierra MD; Alegre-Del Rey EJ; Alarcón de la Lastra-Romero C; Sánchez-Hidalgo M
Farm Hosp; 2019 Nov; 43(6):187-193. PubMed ID: 31705642
[TBL] [Abstract][Full Text] [Related]
11. The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.
Dewilde S; Turk F; Tambour M; Sandström T
Curr Med Res Opin; 2006 Sep; 22(9):1765-76. PubMed ID: 16968580
[TBL] [Abstract][Full Text] [Related]
12. Immune Responses in Rhinovirus-Induced Asthma Exacerbations.
Steinke JW; Borish L
Curr Allergy Asthma Rep; 2016 Nov; 16(11):78. PubMed ID: 27796793
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab for asthma in adults and children.
Normansell R; Walker S; Milan SJ; Walters EH; Nair P
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
[TBL] [Abstract][Full Text] [Related]
14. The discovery and development of omalizumab for the treatment of asthma.
Licari A; Marseglia G; Castagnoli R; Marseglia A; Ciprandi G
Expert Opin Drug Discov; 2015; 10(9):1033-42. PubMed ID: 25979110
[TBL] [Abstract][Full Text] [Related]
15. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.
Holgate ST; Djukanović R; Casale T; Bousquet J
Clin Exp Allergy; 2005 Apr; 35(4):408-16. PubMed ID: 15836747
[TBL] [Abstract][Full Text] [Related]
16. [Anti-immunoglobulin E, a monoclonal antibody to treat respiratory disorders].
Cabrera-Navarro P
Arch Bronconeumol; 2006 May; 42(5):241-5. PubMed ID: 16740240
[TBL] [Abstract][Full Text] [Related]
17. Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthma-A Romanian Perspective.
Berghea EC; Balgradean M; Pavelescu C; Cirstoveanu CG; Toma CL; Ionescu MD; Bumbacea RS
Children (Basel); 2021 Dec; 8(12):. PubMed ID: 34943337
[TBL] [Abstract][Full Text] [Related]
18. Plasmacytoid dendritic cells drive acute asthma exacerbations.
Chairakaki AD; Saridaki MI; Pyrillou K; Mouratis MA; Koltsida O; Walton RP; Bartlett NW; Stavropoulos A; Boon L; Rovina N; Papadopoulos NG; Johnston SL; Andreakos E
J Allergy Clin Immunol; 2018 Aug; 142(2):542-556.e12. PubMed ID: 29054692
[TBL] [Abstract][Full Text] [Related]
19. Treating severe allergic asthma with anti-IgE monoclonal antibody (omalizumab): a review.
D'Amato G; Stanziola A; Sanduzzi A; Liccardi G; Salzillo A; Vitale C; Molino A; Vatrella A; D'Amato M
Multidiscip Respir Med; 2014; 9(1):23. PubMed ID: 24735949
[TBL] [Abstract][Full Text] [Related]
20. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production.
Message SD; Laza-Stanca V; Mallia P; Parker HL; Zhu J; Kebadze T; Contoli M; Sanderson G; Kon OM; Papi A; Jeffery PK; Stanciu LA; Johnston SL
Proc Natl Acad Sci U S A; 2008 Sep; 105(36):13562-7. PubMed ID: 18768794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
